NGR-hTNF in Combination With an Anthracycline in Platinum-resistant Ovarian Cancer (NGR018)
Status:
Completed
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
The primary objective of this extension protocol is to evaluate the early safety of a new
schedule of NGR-hTNF given weekly, instead of every 3 or 4 weeks, in a cohort of 12 patients
randomized to the experimental arm A, as compared to a reference cohort of 12 patients
randomized to an anthracycline alone